Identification and Treatment of Lung Cancer Oncogenic Drivers in a Diverse Safety Net Setting
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Molecular testing for EGFR and ALK alterations in non-small cell lung cancer (NSCLC) is increasing in diverse populations. Identifying these oncogenic drivers through testing is linked to improved survival outcomes for patients with NSCLC.
Area Of Science
- Oncology
- Molecular Diagnostics
- Health Disparities
Background
- Advances in targeted therapies for non-small cell lung cancer (NSCLC) have improved patient outcomes.
- Limited data exists on molecular testing and treatment patterns across diverse patient populations with NSCLC.
Purpose Of The Study
- To investigate the patterns of EGFR and ALK testing and treatment in a diverse NSCLC patient cohort.
- To assess the association between molecular testing and survival in this population.
Main Methods
- Retrospective study of 220 diverse patients treated at a safety net healthcare system.
- Analysis of blood and tissue-based testing for EGFR and ALK alterations.
- Cox proportional-hazards regression models to evaluate the impact of testing on survival.
Main Results
- EGFR and ALK testing rates increased significantly from 2017 to 2021.
- EGFR alterations were most frequent in Asian patients (45%); ALK alterations were highest in Hispanic (13%) and Asian (11%) patients.
- Lack of testing was associated with worse survival, while testing positive for EGFR or ALK alterations correlated with improved survival.
Conclusions
- Molecular testing for oncogenic mutations like EGFR and ALK in NSCLC is feasible across all race-ethnicity groups.
- Identification of actionable mutations (EGFR, ALK) is associated with improved survival outcomes in NSCLC patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...